Elderly on Weight Drugs Face Frailty Risks

A large study suggests that older adults taking Eli Lilly's Zepbound (tirzepatide) for obesity may face elevated risks of adverse outcomes, particularly frailty-associated conditions. The research, released as a preprint, indicates that while such conditions are rare, they were linked to significantly higher death risks in tirzepatide users.

Compared to those on non-GLP-1 drugs or who had weight-loss surgery, tirzepatide users who developed malnutrition faced a 25-fold increased risk of death. Similarly, dehydration and muscle wasting presented higher mortality risks for those on tirzepatide. Frailty signs typically appeared after six months of treatment.

Researchers emphasize that these findings do not discourage appropriate use but call for closer monitoring of seniors on these medications. They advise physicians to intervene aggressively at the first sign of frailty, potentially by temporarily stopping tirzepatide. This advice coincides with Medicare's expansion of GLP-1 drug access for obesity starting July 1, 2026.

Experts note that the reduction in lean body mass from GLP-1 induced weight loss might be more critical in older adults with lower muscle reserves. Further research is needed to confirm these findings and explore preventative measures like exercise and protein supplementation.